Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

SGK1 Mediates TGF-β1-Induced Epithelial-Mesenchymal Transition and Fibrosis in Experimental Bronchiolitis Obliterans

ABSTRACT: Bronchiolitis obliterans (BO) represents a major complication limiting long-term survival after lung transplantation, with epithelial-mesenchymal transition (EMT) serving as a core pathogenic mechanism. The TGF-β1 signaling pathway plays a critical role in EMT induction and can activate serum/glucocorticoid-regulated kinase 1 (SGK1) expression. While SGK1 is upregulated in various fibrotic diseases, its functional significance in BO remains undefined. To elucidate SGK1's role in post-transplant BO fibrosis and its interaction with the TGF-β1 pathway, we established a murine heterotopic tracheal transplantation model. Histopathological evaluation and RNA sequencing demonstrated significant SGK1 upregulation in BO lesions by day 28. In vitro, both pharmacological inhibition (EMD638683) and genetic knockdown of SGK1 (siRNA) attenuated TGF-β1-induced EMT in the human small airway epithelial cell line (HSAECs), while concurrently suppressing the expression of extracellular matrix genes (COL1 and FN1). Furthermore, SGK1 inhibition reduced TGF-β1-induced SMAD2/3 phosphorylation. Therapeutic administration of EMD638683, initiated after disease establishment, significantly ameliorated BO pathology. These findings demonstrate that SGK1 promotes BO-associated fibrosis through TGF-β1-mediated EMT and ECM deposition, identifying SGK1 as a potential therapeutic target for post-transplant BO intervention.

ORGANISM(S): Mus musculus

PROVIDER: GSE334327 | GEO | 2026/09/24

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

SGK1 Mediates TGF-β1-Induced Epithelial-Mesenchymal Transition and Fibrosis in Experimental Bronchiolitis Obliterans [SGK]

Project description:Bronchiolitis obliterans (BO) represents a major complication limiting long-term survival after lung transplantation, with epithelial-mesenchymal transition (EMT) serving as a core pathogenic mechanism. The TGF-β1 signaling pathway plays a critical role in EMT induction and can activate serum/glucocorticoid-regulated kinase 1 (SGK1) expression. While SGK1 is upregulated in various fibrotic diseases, its functional significance in BO remains undefined. To elucidate SGK1's role in post-transplant BO fibrosis and its interaction with the TGF-β1 pathway, we established a murine heterotopic tracheal transplantation model. Histopathological evaluation and RNA sequencing demonstrated significant SGK1 upregulation in BO lesions by day 28. In vitro, both pharmacological inhibition (EMD638683) and genetic knockdown of SGK1 (siRNA) attenuated TGF-β1-induced EMT in the human small airway epithelial cell line (HSAECs), while concurrently suppressing the expression of extracellular matrix genes (COL1 and FN1). Furthermore, SGK1 inhibition reduced TGF-β1-induced SMAD2/3 phosphorylation. Therapeutic administration of EMD638683, initiated after disease establishment, significantly ameliorated BO pathology. These findings demonstrate that SGK1 promotes BO-associated fibrosis through TGF-β1-mediated EMT and ECM deposition, identifying SGK1 as a potential therapeutic target for post-transplant BO intervention.

2026-09-29 | GSE349082 | GEO

SGK1 Mediates TGF-β1-Induced Epithelial-Mesenchymal Transition and Fibrosis in Experimental Bronchiolitis Obliterans

Project description:SGK1 Mediates TGF-β1-Induced Epithelial-Mesenchymal Transition and Fibrosis in Experimental Bronchiolitis Obliterans

| PRJNA1474801 | ENA

Spatial Transcriptomics Analysis of Macrophage-to-Myofibroblast Transition in Bronchiolitis Obliterans Following Hematopoietic Stem Cell Transplantation

Project description:Bronchiolitis obliterans (BO) is a severe, fibrotic manifestation of chronic graft-versus-host disease (GVHD) after hematopoietic stem cell transplantation (HSCT). Macrophage-derived TGF-β is linked to GVHD-related fibrosis; however, its role in BO remains unclear. Given emerging evidence of macrophage-to-myofibroblast transition (MMT) in fibrosis, this study aimed to investigate whether MMT contributes to BO development. We analyzed lung samples from three HSCT recipients with BO who underwent lung transplantation, with tissues from two patients with lung cancer as controls. Spatial transcriptomics was performed to profile gene expression in foamy macrophages across anatomical regions and histological stages, compared to control peribronchiolar regions.

2026-01-22 | GSE316672 | GEO

Mesenchymal stem cells reversibly dedifferentiate myofibroblasts to fibroblast-like cells by down-regulating the TGF-β-SMAD2/3 pathway

Project description:Bronchiolitis obliterans (BO) is a pulmonary chronic graft-versus-host disease (cGVHD), which is a noninfectious, irreversible, and poor prognostic complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Fibroblast-myofibroblast transition (FMT)-derived myofibroblasts (MFB) are the main effector cells involved in the development of BO. Through multiple regulations, the anti-fibrotic potential of mesenchymal stem cells (MSC) has been widely studied and was implied with potential clinical value. However, the MSC-mediated regulation of FMT and underlying mechanisms remained largely undefined. By identifying TGF-β1 hypertension as the pivotal landmark during the profibrotic FMT, TGF-β1-induced MFB and uMSC co-culture models were established and utilized to investigate regulations by uMSC on FMT in vitro. Methods including RNA sequencing (RNA-seq), Western blot, qPCR and flow cytometry were used. Our results revealed that uMSC reversibly dedifferentiated MFB into a group of FB-like cells by modulating the TGF-β-SMAD2/3 signaling. Importantly, these proliferation-boosted FB-like cells remained sensitive to TGF-β1 and could be re-induced into MFB. Our findings highlighted the reversibility of uMSC-mediated inhibitions on FMT through TGF-β-SMAD2/3 signaling, which may explain MSC's inconsistent clinical efficacies in treating BO and other fibrotic diseases. These dedifferentiated FB-like cells are still sensitive to TGF-β1 and may further deteriorate MFB phenotypes unless the profibrotic environment is corrected.

2023-02-18 | GSE225159 | GEO

Vicious circle of LSD1 and TGF β1 promotes EMT of gastric cancer

Project description:Vicious circle of some key proteins is critical in the process of tumor development. Nevertheless, the mechanism of how the epigenetic modifiers are involved in was seldom reported and has not been clearly illustrated. We found the expression of lysine specific demethylase 1 (LSD1), the first identified histone lysine demethylase, is positively correlated with transforming growth factor beta 1 (TGF β1) in gastric cancer tissues and can be promoted by TGF β1 activated (p-EKR)-(NF-κB)-p300 signaling pathway, which resulted in the progression of epithelial-mesenchymal transition (EMT) in human gastric cancer cells. On the other hand, abrogation of LSD1 leads to the down regulation of TGF β1 as well as the EMT. But in benign cells, this circle was blocked by TGF β1 induced inactivation of ERK, which suggested the distinct roles of TGF β1 against LSD1 in gastric cancer cells and benign cells. This vicious cycle may illustrate a novel mechanism for EMT in gastric cancer mediate by TGF β1 and LSD1 but not in benign cells and may serve as a new strategy for the prevention of EMT for gastric cancer.

2016-07-19 | GSE84487 | GEO

Transforming growth factor-β1 induces super-enhancers at the loci of the epithelial-mesenchymal transition-related genes in human keratinocyte HaCaT cells

Project description:An enhancer is a genomic DNA sequence that substantially enhances the transcriptional activity of a target gene by recruiting transcription factors. The large clusters of enhancers identified through the ChIP-seq analysis of histone H3 lysine 27 acetylation (H3K27ac) are called super-enhancers (SEs). This study examined the dynamics of SEs during transforming growth factor (TGF)-β1-mediated epithelial-mesenchymal transition (EMT) in the human keratinocyte cell line HaCaT. Initially, we identified the constitutive and the TGF-β1 signal-dependent SE regions across the HaCaT genome. The TGF-β1-induced SEs were detected at the loci of genes associated with the cell cycle, cell death, and extracellular matrix organization. Notably, the EMT-related mesenchymal genes such as FN1 and SERPINE1 gained the SEs on their loci in response to TGF-β1. Next, we investigated the functional role of BRD4, a transcriptional mediator that binds to the SEs, in the expression of TGF-β1-induced SE-associated genes. JQ-1, a potent inhibitor of BRD4, effectively reduced the TGF-β1-induced mRNA expression of FN1 and SERPINE1. In conclusion, this study demonstrated that the rearrangement of SEs is crucial for the transcriptional regulation of the TGF-β1-induced EMT in HaCaT cells.

2026-03-03 | GSE290958 | GEO

EMT-induced stemness and tumorigenicity are fueled by an oncogenic EGF/Ras pathway

Project description:Pre-EMT GIF14 cells treated with TGF-β1

2014-02-19 | GSE44055 | GEO

Gene expression signitures in ARPE-19 cells treated with or without TGF-β1

Project description:To identify the dysregulated lncRNA and mRNA expression in ARPE-19 cells underwent EMT, we established a TGF-β1 induced EMT model of ARPE-19 cells. ARPE-19 cells were treated with or without 10 ng/ml TGF-β1 for 48 h. Total RNA are extracted and subjected to microarray assay (Arraystar Human LncRNA Microarray V3.0)

2021-08-11 | GSE105053 | GEO

Transcriptome changes in 2,3-butanedione induced bronchiolitis obliterans in rats

Project description:Bronchiolitis obliterans (BO) is a destructive fibrotic lung disease, which can be partly induced by 2,3-butanedione (also known as diacetyl, DA). However, the mechanism underlying the effects of DA on BO is not clear. In the present study, a bioinformatics analysis was performed using DA-treated or untreated lung tissues of rats.

2025-01-22 | GSE279398 | GEO

miR-134/487b/655 Cluster regulates TGF-β-induced epithelial-mesenchymal transition and drug resistance to Gefitinib by targeting MAGI2 in lung adenocarcinoma cells.

Project description:Epithelial-mesenchymal transition (EMT) has recently been recognized as a key element of cell invasion, migration, metastasis, and drug resistance in several types of cancer, including non-small cell lung cancer (NSCLC). Our aim was to clarify microRNA (miRNA) -related mechanisms underlying EMT followed by acquired resistance to epidermal growth factor receptor tyrosine-kinase inhibitor (EGFR-TKI) in NSCLC. MiRNA expression profiles were examined before and after transforming growth factor-beta1 (TGF-β1) exposure in four human adenocarcinoma cell lines with or without EMT. Correlation between expressions of EMT-related miRNAs and resistance to EGFR-TKI gefitinib was evaluated. MiRNA array and quantitative RT-PCR revealed that TGF-β1 significantly induced overexpression of miR-134, miR-487b, and miR-655, which belong to the same cluster located on chromosome 14q32, in lung adenocarcinoma cells with EMT. MAGI2 (membrane-associated guanylate kinase, WW and PDZ domain-containing protein 2), a predicted target of these miRNAs and a scaffold protein required for PTEN (phosphatase and tensin homolog), was diminished in A549 cells with EMT after the TGF-β1 stimulation. Overexpression of miR-134 and miR-487b promoted the EMT phenomenon and affected the drug resistance to gefitinib, whereas knockdown of these miRNAs inhibited the EMT process and reversed TGF-β1-induced resistance to gefitinib. Our study demonstrated that the miR-134/487b/655 cluster contributed to the TGF-β1-induced EMT phenomenon and affected the resistance to gefitinib by directly targeting MAGI2, whose suppression subsequently caused loss of PTEN stability in lung cancer cells. The miR-134/miR-487b/miR-655 cluster may be new therapeutic targets in advanced lung adenocarcinoma patients, depending on the EMT phenomenon.

2013-10-30 | GSE51828 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data